Whitehawk Therapeutics (WHWK) Asset Utilization Ratio (2020 - 2025)
Whitehawk Therapeutics (WHWK) reported Asset Utilization Ratio of 0.04 for Q4 2025, down 86.5% year-over-year from 0.33 in Q4 2024, and down 45.64% on a QoQ basis from 0.08 in Q3 2025.
Whitehawk Therapeutics (WHWK) has 6 years of Asset Utilization Ratio data on file, last reported at 0.04 in Q4 2025.
- Quarterly Asset Utilization Ratio fell 86.5% year-over-year to 0.04 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.04 (down 86.5% YoY) and the FY2025 annual result came in at 0.06, down 74.79% from the prior year.
- Asset Utilization Ratio fell to 0.04 in Q4 2025 per WHWK's latest filing, from 0.08 in the prior quarter.
- Across five years, Asset Utilization Ratio topped out at 0.98 in Q1 2021 and bottomed at 0.04 in Q4 2025.
- The 5-year median for Asset Utilization Ratio is 0.15 (2022), against an average of 0.2.
- The widest annual swing landed in 2021, when Asset Utilization Ratio plunged 89.85%; it then soared 122.56% in 2023.
- Tracing WHWK's Asset Utilization Ratio over 5 years: stood at 0.09 in 2021, then fell by 6.95% to 0.08 in 2022, then soared by 122.56% to 0.18 in 2023, then surged by 86.06% to 0.33 in 2024, then sank by 86.5% to 0.04 in 2025.
- Per Business Quant, the three latest WHWK Asset Utilization Ratio figures stand at 0.04 (Q4 2025), 0.08 (Q3 2025), and 0.1 (Q2 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 0.60 |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 0.47 |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 0.29 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 0.37 |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 0.85 |
| 10 | Whitehawk Therapeutics | 312.26 Mn | 189.22 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 0.04 |
| Sep 30, 2025 | 0.08 |
| Jun 30, 2025 | 0.10 |
| Mar 31, 2025 | 0.18 |
| Dec 31, 2024 | 0.33 |
| Sep 30, 2024 | 0.27 |
| Jun 30, 2024 | 0.22 |
| Mar 31, 2024 | 0.20 |
| Dec 31, 2023 | 0.18 |
| Sep 30, 2023 | 0.16 |
| Jun 30, 2023 | 0.13 |
| Mar 31, 2023 | 0.11 |
| Dec 31, 2022 | 0.08 |
| Sep 30, 2022 | 0.15 |
| Jun 30, 2022 | 0.15 |
| Mar 31, 2022 | 0.11 |
| Dec 31, 2021 | 0.09 |
| Sep 30, 2021 | 0.14 |
| Jun 30, 2021 | 0.37 |
| Mar 31, 2021 | 0.98 |
| Dec 31, 2020 | 0.85 |
| Sep 30, 2020 | 0.71 |
| Jun 30, 2020 | 0.86 |